Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab for ANCA-Associated Refractory Vasculitis (ALEVIATE)
2009-017087-17Phase 4Completed
- Sponsor
- Addenbrooke's Hospital
- Start
- Jul 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of alemtuzumab in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), sponsored by Addenbrooke's Hospital. Started Jul 2010; status: completed.
02
Drugs
alemtuzumab
03
Conditions
anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on 2009-017087-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017087-17.